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Background: In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed
to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms.
Methods: This was a randomized, open-label, parallel-group multicenter study. Helicobacter pylori-negative,
endoscopically uninvestigated patients≥ 20 years of age with upper gastrointestinal symptoms of at least moderate
severity (Global Overall Symptom score [GOS]≥ 4 on a 7-point Likert scale) were randomized to treatment with
omeprazole (10 mg once daily), famotidine (10 mg twice daily), mosapride (5 mg three times daily) or teprenone
(50 mg three times daily). The primary endpoint was sufficient relief of upper gastrointestinal symptoms after 4 weeks
of treatment (GOS≤ 2). UMIN clinical trial registration number: UMIN000005399.
Results: Of 471 randomized patients, 454 were included in the full analysis set. After 4 weeks of treatment, sufficient
symptom relief was achieved by 66.9% of patients in the omeprazole group, compared with 41.0%, 36.3% and 32.3% in
the famotidine, mosapride and teprenone groups, respectively (all, p< 0.001 vs omeprazole). There were no
treatment-related adverse events.
Conclusions: The favorable efficacy and safety profiles of omeprazole in relieving uninvestigated upper gastrointestinal
symptoms support its use as first-line treatment in this patient group in Japan. Patients who show no improvement in
symptoms despite PPI use, and those with alarm symptoms (such as vomiting, GI bleeding or acute weight loss) should
receive further investigation, including prompt referral for endoscopy.
Trial registration: UMIN000005399.
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Upper gastrointestinal (GI) symptoms are common in
Japan and their prevalence may be increasing. In a large,
international population-based survey of 500 Japanese
participants, 26% had experienced upper GI symptoms
during the previous 3 months and had a reduced quality
of life as a consequence [1,2]. Similarly, in a survey of
231 Japanese employees, 20% reported having frequent
upper GI symptoms in the previous 3 months [3]. An
international review of the prevalence of gastroesopha-
geal reflux disease (GERD) showed that, although the
prevalence of heartburn and/or regurgitation on at least
2 days per week was lower in Japan (about 7%) than in
Western populations, it was increasing [4].
Helicobacter pylori infection is a common cause of
underlying peptic ulcer disease and might be a cause of
upper GI symptoms [5]. Hence, a H. pylori ‘test and
treat’ strategy is the mainstay for managing patients with
uninvestigated upper GI symptoms [6,7]. Another cause
of upper GI symptoms is GERD [8]. The presence of
upper GI symptoms in the absence of GERD or organic
findings at endoscopy is termed functional dyspepsia.
The Rome III classification of functional GI disorders
lists symptoms of postprandial fullness, early satiety, epi-
gastric pain and epigastric burning as diagnostic criteria
for functional dyspepsia when there is no evidence of
structural disease that is likely to explain the symptoms
[9]. Bloating, postprandial nausea and excessive belching
can also support a diagnosis of functional dyspepsia [9].
By contrast, the predominant symptoms of heartburn
and/or regurgitation are excluded from the criteria for
dyspepsia and are instead included in the diagnostic cri-
teria for GERD, with or without reflux esophagitis [8,9].
However, patients with upper GI diseases/disorders often
present with multiple symptoms, and symptoms corre-
sponding to GERD and dyspepsia frequently coexist in
the same patient [10,11]. For example, in a Japanese
study by Adachi et al. of 221 patients with GERD who
had reflux esophagitis, the mean number of upper GI
symptoms reported by each patient was 5.4 [10].
Similarly, in the Canadian Adult Dyspepsia Empirical
Treatment–Prompt Endoscopy (CADET-PE) study by
Thomson et al., of 1040 patients with uninvestigated
dyspeptic symptoms, 80% had at least six upper GI
symptoms, including heartburn, regurgitation, upper
abdominal pain and upper abdominal fullness, while
< 0.1% had only one symptom [11].
Acid suppression with proton pump inhibitors (PPIs)
is effective in relieving heartburn and regurgitation, and
the American College of Gastroenterology guidelines
recommend PPIs as the mainstay therapy for GERD [12].
PPIs are also recommended as first-line pharmacother-
apy for the management of dyspepsia [13,14], and are
more effective than histamine H2-receptor antagonists orprokinetic agents in the treatment of upper GI symptoms
in patients with H. pylori-negative dyspepsia [15]. There
is, however, a need for up-to-date management guide-
lines for GERD (with and without reflux esophagitis) and
dyspepsia in Japan [16,17].
Studies on the efficacy of PPIs for upper GI symptoms
are lacking for Japanese populations, which have a lower
prevalence of heartburn and regurgitation than Western
populations [1,2,4]. Therefore, in an effort to rectify this
situation, we conducted a study of four GI medications,
the omeprazole-controlled randomized study in Japanese
patients with upper GI symptoms (J-FOCUS). The study
included endoscopically uninvestigated, H. pylori-negative
patients with upper GI symptoms. The aim of J-FOCUS
was to compare the symptomatic efficacy of the PPI ome-
prazole with that of three other GI drugs with different
modes of action: the histamine H2-receptor antagonist
famotidine, the prokinetic agent mosapride and the muco-
sal protective agent teprenone.
Methods
Study design
This randomized, multicenter, parallel-group, open-label
study was conducted in Japan between February 2007
and June 2008. The local ethics committee at each study
center approved the study protocol. We obtained written
informed consent from all of the patients.
Setting and participants
J-FOCUS was conducted at 162 centers in Japan. The
study enrolled patients who visited a participating clinic
or hospital because of GI symptoms. Patients aged ≥ 20
years of age were eligible for inclusion if they had
chronic or recurrent episodes of at least one of eight
specific upper GI symptoms (epigastric pain, heartburn,
regurgitation, postprandial fullness, nausea/vomiting,
belching, early satiety and/or bloating), with one or more
of the symptoms being of at least moderate severity
(Global Overall Symptom [GOS] score ≥ 4) in the previ-
ous week. All patients underwent urine antibody testing
(Rapirun® H. pylori Antibody Detection Kit, Otsuka
Pharmaceutical Co., Ltd., Tokyo, Japan). This test was
reported to show high sensitivity (100%) and accuracy
(95.2%) for diagnosis of H. pylori infection relative to
biopsy-based testing [18]. Individuals who were H. pylori
positive, requiring H. pylori eradication therapy, were
not included in this study. Patients with a history of
H. pylori eradication were excluded because this could
introduce errors with antibody testing. Patients were also
excluded if they had undergone an endoscopy in the pre-
vious 3 months; had alarm symptoms (such as vomiting,
GI bleeding or acute weight loss) requiring endoscopy;
were judged by the investigator to require a prompt en-
doscopy; had a confirmed or suspected malignant lesion;
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bowel syndrome or other comorbidities (including hep-
atic, renal or cardiac disease); had severe mental illness;
were or might possibly be pregnant or were lactating; or
were judged to be ineligible for study entry by the
investigator.
PPIs, H2-receptor antagonists, prokinetic agents, gastric
mucosal protective agents, anticholinergics, antidepres-
sants, anxiolytics, steroids (other than topical steroids),
non-steroidal anti-inflammatory drugs, aspirin or bispho-
sphonates were discontinued at least 1 week before study
entry and were not allowed during the study period.
Randomization and interventions
Eligible patients were randomly assigned in a 2:2:2:1 pro-
portion, using a central computer-generated randomization
list managed by a clinical research coordinator at each cen-
ter. During screening/enrollment, the physician recorded
the subject’s characteristics and provided this information
to the clinical research coordinator, who then allocated the
subject an ID and study drug based on the sealed allocation
tables prepared by the secretariat. Patients were allocated
using this method to receive omeprazole (10 mg once
daily), famotidine (10 mg twice daily), mosapride (5 mg
three times daily) or teprenone (50 mg three times daily)
for 4 weeks. All of the drugs were prescribed routinely and
administered orally. The doses of each drug were in line
with the authorized doses that are considered optimal for
the treatment of dyspepsia or GERD symptoms in Japan.
Rescue medication was not allowed. Patients visited the
clinic at study entry and at 4 weeks after the start of treat-
ment, and completed the GOS assessment. An optional
additional clinic visit could take place at 2 weeks after the
start of treatment. There were no deviations in the alloca-
tion of subjects based on their background characteristics.
Outcomes and follow-up
The primary endpoint was the proportion of patients
with sufficient overall symptom relief after 4 weeks of
treatment, which was defined as, at most, minimal symp-
tom severity (GOS ≤ 2) for all symptoms on the GOS.
The GOS has been validated in patients with dyspepsia
[19], and has been used in clinical studies of patients
with dyspepsia to assess symptoms and treatment success
[15,20,21]. It measures the severity of eight symptoms
(epigastric pain, heartburn, regurgitation, postprandial full-
ness, nausea/vomiting, belching, early satiety and bloating)
on a 7-point Likert scale (1= no problem [no symptoms];
2 =minimal problem [can be easily ignored without effort];
3 =mild problem [can be ignored with effort]; 4 =moder-
ate problem [cannot be ignored but does not influence
daily activities]; 5 =moderately severe problem [cannot be
ignored and occasionally limits daily activities]; 6 = severe
problem [cannot be ignored and often limits concentrationon daily activities]; 7 = very severe problem [cannot be
ignored, markedly limits daily activities and often requires
rest]. The completed GOS was collected by the investiga-
tors who were not allowed to change any outcome
reported by the patients.
Secondary endpoints were the proportion of patients
with complete overall symptom relief (GOS= 1) after
4 weeks of treatment for all symptoms on the GOS; the
proportion of patients with sufficient overall symptom
relief after 2 weeks of treatment; the proportion of
patients with complete overall symptom relief after
2 weeks of treatment; the proportion of patients with
symptom improvement after 4 weeks of treatment (de-
crease in GOS by≥ 2 grades for each symptom scored ≥ 3
at baseline on the GOS); and the proportion of patients
with symptom aggravation (increase in GOS by≥ 2
grades for each symptom scored ≤ 5 at baseline on the
GOS) after 4 weeks of treatment.
Upper GI symptoms were classified into one of the
following three categories: (1) GERD symptoms, if the
symptom with the highest GOS score was heartburn or
regurgitation; (2) dyspeptic symptoms, if the symptom
with the highest GOS score was epigastric pain, post-
prandial fullness or early satiety; (3) and other upper GI
symptoms, if the symptom with the highest GOS score
was nausea, vomiting, belching or bloating. Coexistence
was defined as the presence of symptoms from more than
one symptom category with a score of≥ 4. Treatment-
related adverse events were assessed and recorded at each
follow-up visit.
Statistical analysis
Based on prior studies [10,15], we estimated the propor-
tion of patients with symptom relief after 4 weeks of
treatment at 68% for omeprazole and 50% for famoti-
dine. From these values, we calculated that 127 patients
in each of the omeprazole and famotidine treatment
groups would provide 80% power to detect a significant
difference between the two groups. We aimed for a simi-
lar number of patients for the mosapride group. The ef-
fect of teprenone on dyspeptic or GERD symptoms was
assumed to be lower than that of the other agents [22].
Considering the symptom severity of included patients,
it was planned for ethical reasons to keep the group allo-
cated to teprenone as small as possible. It was estimated
that the effect of teprenone could be confirmed with half
the number of individuals allocated to the other agents.
Safety variables were analyzed using all randomized
patients (i.e., intention-to-treat population). Efficacy vari-
ables were analyzed using the full analysis set, which
comprised all patients who attended the baseline visit
and at least one follow-up visit. Patients who did not re-
turn after the initial visit were excluded from efficacy
analyses. The primary variable, the proportion of patients
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treatment, was compared between the omeprazole group
and the other treatment groups using χ2 tests. A value of
p< 0.0167 in a two-sided test with Bonferroni correction
was considered statistically significant. For secondary
variables, no corrections were made for multiple com-
parisons. Multivariate logistic regression analysis was
also conducted to examine potential determinants of
treatment efficacy.Results
Study sample
In total, of 533 patients with upper GI symptoms who
were screened, 62 were excluded (H. pylori positive,
n = 60; GOS≤ 3, n = 1; incomplete questionnaire, n = 1)
and 17 were lost to follow-up after randomization. Thus,
471 patients were included in the intention-to-treat ana-
lysis and 454 patients were included in the full analysis
set (Figure 1). In the 1 month before study entry, 83% of
patients were not prescribed a GI drug: no patient was
prescribed a PPI or H2-receptor antagonist, 5% were pre-
scribed a prokinetic and 12% were prescribed other GI
drugs. The characteristics of the patients at baseline were
similar in the four treatment groups (Table 1).Figure 1 Study flow diagram. *patients who completed the Global OveraSymptoms at baseline
The mean number of upper GI symptoms per patient
was 6.0 at baseline. In terms of symptoms of at least
moderate severity (i.e. GOS ≥ 4) postprandial fullness was
the most frequent, being reported by 69.1% of patients, fol-
lowed by epigastric pain, heartburn and bloating (Figure 2).
Overall, 41.4% of patients had more than one predominant
symptom type (‘GERD symptoms’, ‘dyspeptic symptoms’
and ‘other upper GI symptoms’; Figure 3). Ninety patients
reported both GERD symptoms and dyspeptic symptoms
as their predominant symptom type. There were no signifi-
cant differences in the proportions of patients with each
symptom between the four treatment groups at study entry
(Table 2).
Primary outcome
The proportion of patients with sufficient overall symp-
tom relief after 4 weeks of treatment was significantly
higher in the omeprazole group than in the other treat-
ment groups. In total, 66.9% of patients in the omepra-
zole group reported sufficient overall symptom relief
after 4 weeks of treatment, compared with 41.0%, 36.3%
and 32.3% in the famotidine, mosapride and teprenone
groups, respectively (p< 0.001 vs omeprazole; Figure 4).
Similar results were obtained in the intent-to-treatll Symptom assessment; ITT, intention-to-treat; FAS, full analysis set.









Men, n (%) 60 (43.2%) 48 (37.2%) 40 (33.9%) 29 (42.6%)
Age y, n (%)
≤39 72 (51.8%) 70 (54.3%) 61 (51.7%) 41 (60.3%)
40–59 52 (37.4%) 51 (39.5%) 45 (38.1%) 21 (30.9%)
≥60 15 (10.8%) 8 (6.2%) 12 (10.2%) 6 (8.8%)
Age, y (mean±SD) 40.9 ± 13.6 39.4 ± 12.6 40.0 ± 13.2 40.0 ± 12.9
BMI, kg/m2
<20 36 (25.9%) 42 (32.6%) 33 (28.0%) 20 (29.4%)
20–24 79 (56.8%) 65 (50.4%) 64 (54.2%) 39 (57.4%)
≥25 24 (17.3%) 22 (17.1%) 21 (17.8%) 9 (13.2%)
BMI, kg/m2 (mean± SD) 22.3 ± 3.5 21.9 ± 3.0 22.0 ± 3.2 21.7 ± 3.0
Smoking status (cigarettes/day)
None 101 (72.7%) 101 (78.3%) 93 (78.8%) 47 (69.1%)
<20 35 (25.2%) 20 (15.5%) 19 (16.1%) 16 (23.5%)
≥20 3 (2.2%) 8 (6.2%) 6 (5.1%) 5 (7.4%)
Alcohol intake
None 59 (42.4%) 55 (42.6%) 42 (35.6%) 22 (32.4%)
Occasionally 58 (41.7%) 53 (41.1%) 45 (38.1%) 32 (47.1%)
Every day 22 (15.8%) 21 (16.3%) 31 (26.3%) 14 (20.6%)
Concurrent disease
Absent 111 (79.9%) 114 (88.4%) 98 (83.1%) 62 (91.2%)
Present 28 (20.1%) 15 (11.6%) 20 (16.9%) 6 (8.8%)
SD, standard deviation; BMI, body mass index.
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prazole, 62.7%; famotidine, 37.9%; mosapride, 32.8%; and
teprenone, 24.2%; all p< 0.001 vs omeprazole).
Secondary outcomes
The proportion of patients with complete overall symp-
tom relief after 4 weeks of treatment was significantlyFigure 2 Upper gastrointestinal symptoms in 454 patients at baselinehigher in the omeprazole group than in any of the other
three treatment groups. In total, 27.8% of the patients
treated with omeprazole reported complete overall
symptom relief after 4 weeks of treatment, as compared
with 9.8%, 8.0% and 6.2% of patients treated with famoti-
dine, mosapride and teprenone, respectively (all, p< 0.001
vs omeprazole)., as scored on the Global Overall Severity (GOS) scale.
Figure 3 Coexistence of predominant gastroesophageal reflux
disease (GERD) symptoms, predominant dyspeptic symptoms
and predominant other upper gastrointestinal symptoms,
according to the symptom with the highest Global Overall
Severity score at baseline. A joint highest score for more than one
symptom was possible. GERD symptoms included heartburn and
regurgitation; dyspeptic symptoms included epigastric pain,
postprandial fullness and early satiety; and other symptoms included
nausea/vomiting, belching and bloating.
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ment was reported by 37.3% of patients in the omeprazole
group, compared with 20.0% in the famotidine group
(P=0.003 vs omeprazole), 15.1% in the mosapride group
(p< 0.001 vs omeprazole) and 20.0% in the teprenone
group (p= 0.018 vs omeprazole). The proportion of patients
with complete overall symptom relief after 2 weeks of treat-
ment was 8.7% in the omeprazole group, compared with
7.0% in the famotidine group (p= 0.610 vs omeprazole),
0.9% in the mosapride group (p=0.008 vs omeprazole) and





Stomach pain 87 (14.6) 90
Heartburn 89 (15.0) 75
Regurgitation 66 (11.1) 54
Postprandial fullness 113 (19.0) 100
Vomiting 59 (9.9) 51
Belching 46 (7.7) 31
Early satiety 60 (10.1) 47
Bloating 75 (12.6) 65
Values are n (%). There were no significant differences in rates of each symptom acThe largest effect on symptom improvement was
observed in the omeprazole group for each of the eight
symptoms assessed by the GOS (Figure 5). By contrast,
the proportion of patients with symptom aggravation after
4 weeks of treatment was highest in the teprenone group
and lowest in the omeprazole group: 1.5% of patients in
the omeprazole group reported symptom aggravation after
4 weeks of treatment, compared with 4.9% in the famoti-
dine group (p= 0.118 vs omeprazole), 6.2% in the mosa-
pride group (p= 0.051 vs omeprazole) and 10.8% in the
teprenone group (p=0.003 vs omeprazole).
Compliance was assessed as the proportion of patients
who took at least 75% of their doses over the treatment
period. The rates of compliance were 96%, 91%, 84% and
89% in the omeprazole, famotidine, mosapride, and tepre-
none groups, respectively. None of the patients included
in the safety analysis set reported any treatment-related
adverse events at either follow-up visit.
Factors affecting outcome
Multivariate logistic regression analysis showed that
patients in the famotidine, mosapride and teprenone treat-
ment groups were significantly less likely than those in the
omeprazole treatment group to have sufficient overall
symptom relief after 4 weeks of treatment (Table 3). Logis-
tic regression analysis for all treatment groups combined
showed that sufficient overall symptom relief after 4 weeks
of treatment was more likely in patients with fewer than
five upper GI symptoms than in those with five or more
upper GI symptoms at baseline. Symptom relief was also
more likely in patients with predominant dyspepsia symp-
toms than in those without predominant dyspepsia symp-
toms at baseline (Table 3).
The proportion of patients with sufficient overall symp-
tom relief after 4 weeks of treatment was highest in the
omeprazole group, regardless of symptom severity, num-
ber of symptoms and symptom type at baseline (Table 3).
The proportion of patients who reached the primary end-
point in the omeprazole group was higher among those






(17.5) 74 (15.2) 51 (16.1)
(14.6) 64 (13.1) 43 (13.6)
(10.5) 60 (12.3) 35 (11.1)
(19.5) 87 (17.9) 55 (17.4)
(9.9) 54 (11.1) 29 (9.2)
(6.0) 34 (7.0) 30 (9.5)
(9.2) 51 (10.5) 33 (10.4)
(12.7) 63 (12.9) 40 (12.7)
ross treatment groups (all, p> 0.05).
Figure 4 Proportion of patients with sufficient and complete overall relief of their upper gastrointestinal symptoms after 4 weeks of treatment
with omeprazole, famotidine, mosapride or teprenone. Symptoms were scored using the Global Overall Severity (GOS) scale. Sufficient overall symptom
relief was defined as GOS≤2 and complete overall symptom relief was defined as GOS=1 for all symptoms. *p-values given for sufficient symptom relief.
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those with predominant other upper GI symptoms
(62.7%). Other than the omeprazole group, the highest
proportion of patients who reached the primary endpoint
was found in the famotidine group with predominant dys-
peptic symptoms (Table 4).Figure 5 Proportion of patients with improvements in upper gastroin
omeprazole, famotidine, mosapride or teprenone. Symptoms were sco
improvement was defined as a decrease in GOS by≥ 2 grades. *p< 0.05, **Discussion
The results of J-FOCUS, a randomized, open-label study,
showed that omeprazole (10 mg once daily) was signifi-
cantly more effective than famotidine (10 mg twice
daily), mosapride (5 mg three times daily) or teprenone
(50 mg three times daily) for providing sufficient andtestinal symptoms after 2 weeks and 4 weeks of treatment with
red using the Global Overall Severity (GOS) scale, and symptom
p< 0.01 vs omeprazole.
Table 3 Demographic and clinical characteristics and their
association with sufficient overall symptom relief after
4 weeks of treatment on multivariate logistic regression
analysis











≥ 60 1.0 (0.98–1.01)
BMI, kg/m2
< 25 1.00







Number of symptoms at baseline
< 5 1.00
≥ 5 0.48 (0.29–0.81)
Symptom severity






*Compared with patients who did not have this symptom type. OR, odds ratio;
CI, confidence interval; BMI, body mass index; FD, functional dyspepsia; GERD,
gastroesophageal reflux disease.
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treatment in endoscopically uninvestigated, H. pylori-
negative patients. Symptoms were assessed using a previ-
ously validated symptom scale (GOS [19]), which has
already been used in clinical studies to measure symp-
toms and treatment success in patients with dyspepsia
with and without H. pylori infection [15,20,21]. In the
present study, 66.9% of patients treated with omeprazole
reached the primary endpoint of sufficient overall relief
of upper GI symptoms (GOS ≤ 2) after 4 weeks of treat-
ment, as compared with 41.0%, 36.3% and 32.3% of
patients treated with famotidine, mosapride and tepre-
none, respectively (all, p< 0.001 vs omeprazole). Theproportion of patients with complete overall symptom
relief (GOS= 1) after 4 weeks of treatment was about
three-fold higher in the omeprazole group (27.8%) than
in the other three treatment groups (9.8%, 8.0% and
6.2%, respectively; all, p< 0.001 vs omeprazole). Within
the omeprazole group, the proportion of patients with
sufficient overall symptom relief after 4 weeks of treat-
ment was highest in patients with predominant GERD
symptoms, followed by those with predominant dyspep-
sia symptoms. None of the included patients was pre-
scribed a PPI within 1 month of entering the study.
Because PPIs are not available over-the-counter in Japan,
it is very unlikely that any of the included patients had
used a PPI in the month before the study.
Our results support those of 512 Canadian patients
with H. pylori-negative dyspepsia in the randomized,
double-blind CADET–H. pylori Negative (HN) study,
which showed that omeprazole was significantly more ef-
fective than ranitidine, cisapride or placebo for relieving
upper GI symptoms after 4 weeks of treatment [15]. Ac-
cordingly, both studies support the use of PPIs as first-
line therapy for the treatment of dyspepsia.
Patients in J-FOCUS presented with multiple symp-
toms: the mean number of upper GI symptoms reported
by each patient at study entry was six. The prevalence
and severity of upper GI symptoms in J-FOCUS were
comparable with those described in Japanese patients
with GERD who had reflux esophagitis [10,23]. The
mean number of upper GI symptoms per patient was 5.4
in the study by Adachi et al., which included patients
with GERD who had reflux esophagitis, and a similarly
high symptom load was observed in the CADET-PE
study, in which 80% of patients with uninvestigated dys-
pepsia had at least six upper GI symptoms [10,11]. We
observed substantial coexistence of different symptom
types, with 41.4% of patients in J-FOCUS having coexist-
ing GERD, dyspepsia and/or other upper GI symptoms.
Coexistence of GERD and dyspepsia was common, with
19.8% of patients reporting both GERD and dyspepsia as
their predominant symptom types. Adachi et al. also
observed substantial coexistence of symptoms in patients
with GERD [10]. In that study, the most prevalent symp-
toms were heartburn and regurgitation, which were
reported by 71% and 68% of patients, respectively, but
these were closely followed by upper abdominal heavi-
ness (63%), upper abdominal pain (54%) and upper ab-
dominal fullness (53%). In our study, a lower number of
upper GI symptoms at baseline was associated with
treatment success, but symptom severity did not affect
treatment success on logistic regression analysis.
Within each treatment group, no pronounced differ-
ences in symptom response were observed among the
eight symptoms assessed by the GOS (Figure 5). Never-
theless, it cannot be ruled out that there may have been
Table 4 Proportion of patients with sufficient overall symptom relief after 4 weeks of treatment with omeprazole,
famotidine, mosapride or teprenone, grouped by symptom severity, number of symptoms and symptom type













Symptom severity* Moderate 104 72.1% 96 44.8% 91 38.5% 47 29.8%
Severe 29 48.3% 26 26.9% 22 27.3% 18 38.9%
Number of symptoms ≤ 4 28 78.6% 36 55.6% 23 43.5% 14 64.3%
≥ 5 105 63.8% 86 34.9% 90 34.4% 51 23.5%
Predominant
symptom type†
GERD 56 76.8% 36 22.2% 35 45.7% 21 23.8%
Dyspepsia 95 68.4% 93 47.3% 77 40.3% 51 33.3%
Other 59 62.7% 46 34.8% 55 30.9% 30 26.7%
*Moderate was defined as a GOS of 4 or 5, and severe as a GOS of 6 or 7.
†Symptoms were categorized as ‘GERD’ if the symptom with the highest score was heartburn or regurgitation, as ‘dyspepsia’, if the symptom with the highest
score was epigastric pain or early satiety, and as ‘other’ if the symptom with the highest score was nausea/vomiting, belching or bloating. A joint highest score for
more than one symptom type was possible. GERD, gastroesophageal reflux disease; GOS, Global Overall Symptom score.
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gastric pain, postprandial fullness or early satiety, as
defined by the Rome III diagnostic criteria. However, we
decided against conducting such analyses, because the
marked coexistence of symptoms that we observed in
this study would have made the data difficult to inter-
pret, and thus, inappropriate to draw conclusions from.
The Rome III diagnostic criteria for functional dyspep-
sia exclude predominant symptoms of troublesome
heartburn and/or regurgitation, which are diagnostic cri-
teria for GERD, with or without reflux esophagitis [8,9].
However, dyspepsia and GERD often coexist in the same
patient, and underlying GERD is a potential cause of dys-
peptic symptoms [24]. GERD develops when the reflux
of stomach contents causes troublesome symptoms and/
or complications [8]. Acid can also play a role in dyspepsia
because acid infusions into the stomach and duodenum
have been shown to increase the perception of upper ab-
dominal symptoms and affect gastroduodenal motor func-
tion in healthy individuals [25-27]. Duodenal acid exposure
is increased in patients with functional dyspepsia and nau-
sea, and this is associated with greater symptom severity
[28]. Dyspepsia has also been linked with increased percep-
tion of postprandial symptoms [29], changes in visceral
sensory function [30], and hypersensitivity to gastric dis-
tension [31].
GI endoscopy is useful to identify the underlying struc-
tural causes of symptoms, but can only be used to diag-
nose a subgroup of patients with upper GI diseases and
disorders. In the CADET-PE study, the prevalence of re-
flux esophagitis on endoscopy was 55% (215/393) among
patients with predominant heartburn and/or regurgita-
tion, and 38% (236/647) among patients with other pre-
dominant upper GI symptoms, while only about 5% of
patients had peptic ulcer disease [11]. In clinical practice
in Japan, endoscopy does not usually form part of the im-
mediate management of patients who visit their medicalpractitioner because of upper abdominal symptoms, unless
alarm symptoms such as GI bleeding, acute weight loss or
severe anemia are present. Instead, symptom control is the
first priority and patients are usually treated with GI drugs
with different modes of action that are selected according
to the type and severity of upper GI symptoms, either in
monotherapy or in combination therapy. However, up-to-
date management guidelines for GERD (with and without
reflux esophagitis) and dyspepsia in Japan need to be
developed [16,17]. These will also need to take into ac-
count the requirement for higher doses of PPIs in view of
the decreasing rate of H. pylori infection in Japan [32].
It is important to consider that the empirical use of
PPIs for patients with uninvestigated GI symptoms
should be done with care. For example, the National In-
stitute of Health and Clinical Excellence in the United
Kingdom [33] recommends that immediate referral for
endoscopy (seen within 2 weeks) is indicated for progres-
sive dysphagia, unintentional weight loss, an epigastric
mass, suspicious barium meal, iron deficiency anemia or
persistent vomiting. They also recommend that, in patients
aged over 55 years, endoscopy should be considered if
symptoms persist despite H. pylori testing and acid sup-
pression therapy. Furthermore, they recommend that em-
pirical full dose PPI therapy is offered for 1 month to
patients with dyspepsia. In the present study, approxi-
mately one-third of patients treated with omeprazole and
up to two-thirds of patients treated with the other drugs
did not attain sufficient symptom relief. In these patients,
further investigations, including endoscopy, may be neces-
sary for diagnosis and to guide future treatments.
J-FOCUS was the first study to compare the efficacy of
omeprazole, famotidine, mosapride and teprenone in
Japanese patients with uninvestigated upper gastrointes-
tinal symptoms. Its randomized, multicenter, parallel-
group design further adds to the strength of this study.
The present study has the following limitations: it was
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fore study entry was not collected; the long-term effects
of each drug beyond the 8-week trial period were not
investigated; and some centers were unable to register
the target number of patients meaning the allocation
ratio (i.e., 2:2:2:1) was not fully met. In addition, the
study did not have a placebo arm, but because we only
enrolled patients with moderate to severe symptoms at
inclusion made this difficult to justify from an ethical
standpoint. Thus, whereas the study provided a compari-
son of symptom relief among active drugs with different
modes of action, the therapeutic gain of each drug com-
pared with placebo could not be determined. However,
the CADET-HN study, which included a placebo arm,
showed that symptom response after 4 weeks of treat-
ment was 51% (95% CI: 43–60%) with omeprazole, 36%
(95% CI: 28–39%) with ranitidine and 31% (95% CI: 22–
39%) with cisapride, compared with 23% (95% CI: 16–
31%) with placebo [15]. No treatment-related adverse
events were reported at either follow-up visit. This may
be related to the 4-week treatment duration, which was
possibly too short for adverse events to occur. However,
we must acknowledge the possibility that some patients
who did not attend the follow-up visits may have discon-
tinued treatment because of adverse events. It is also
possible that discontinuing prior therapies 1 week before
the study might have aggravated symptoms or led to the
onset of new symptoms. However, we were unable to as-
sess this possibility in the present study.
Some other limitations warrant mention. First, we used
a urine antibody test to screen patients for evidence of
H. pylori infection. Although this test shows high sensi-
tivity and accuracy, it has not yet been recommended by
guidelines as a screening test. It is therefore possible that
some patients with H. pylori infection were included in
this study. Although the use of endoscopic biopsy may
have avoided this possibility, this procedure is uncom-
fortable for the patient, time consuming and costly. Urea
breath testing, rapid urease tests or serology are well
established alternatives but, considering their reported
accuracies and specificities [34], they are unlikely to im-
prove the true detection rate over that achieved with the
urine antibody test in this study. Second, it is possible
that the opportunity for the investigators to exclude
patients based on their judgment of eligibility could have
introduced some bias into the study, as the investigators
may have preferentially included patients likely to re-
spond favorably to treatment. However, we deemed this
to be important and useful, as our exclusion criteria
could not cover every eventuality.
Conclusion
Our results from J-FOCUS support the implementation in
Japan of European and US guidelines, which recommendPPIs as first-line treatment in patients with symptoms
of GERD or dyspepsia [13,14]. Our study provides useful
data for the formulation of a treatment flow algorithm in
Japanese patients with upper GI symptoms, especially in
view of the recent decrease in H. pylori infection rate
among young adults in Japan [32]. Other treatment
options, including different doses of PPI and combination
therapy with other GI drugs, may be required in the ap-
proximately 30% of patients whose upper GI symptoms
were not sufficiently relieved after 4 weeks of treatment
with omeprazole. Investigation of the cause of the symp-
toms, such as by endoscopy, should also be considered for
patients with insufficient symptom relief and in those with
symptoms or clinical findings associated with high risk of
serious disease or malignancy.
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